{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.1","upperLimit":"100","value":"97.9"},{"groupId":"OG001","lowerLimit":"63.1","upperLimit":"100","value":"89.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Investigators will calculate RDI for each cohort. Relative dose intensity (RDI) represents the ratio of the amount of a drug actually delivered \\[actual dose intensity (DI)\\] to the amount planned (planned DI). The purpose of calculating RDI is to evaluate whether the planned DI of a chemotherapy treatment was actually achieved which may suggest the feasibility of planned treatment regimen. There are multitude of reports demonstrating a correlation between RDI and survival in cancer treatment. RDI = (total dose received by the patient = mg)/(planned full dose of drug = mg).","dispersionType":"Full Range","groups":[{"description":"Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG000","title":"Cohort A: Maintenance Therapy"},{"description":"Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.\n\nPanobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.","id":"OG001","title":"Cohort B: Maintenance Therapy"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Relative Dose Intensity (RDI) Per Cohort","type":"PRIMARY","unitOfMeasure":"percentage of dose"}